# US 2025/0084040 A1 · SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084040 A1
- Document ID: US20250084040A1
- Status: Published application
- Kind: A1
- Application number: 18/961,307
- Filed: 2024-11-26
- Published: 2025-03-13
- Earliest claimed: 2021-02-28
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Gary E. Schiltz; Rama K. Mishra; Huiying Han; Sarki A. Abdulkadir; Javier Izquierdo-Ferrer; Atul D. Jain
- Web page: https://patentgrep.com/patent/US20250084040A1

## CPC

- C07D 231/18: One oxygen or sulfur atom
- C07D 231/20: One oxygen atom attached in position 3 or 5
- A61P 35/00: Antineoplastic agents
- C07D 231/06: having one double bond between ring members or between a ring member and a non-ring member
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 239/26: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 249/06: with aryl radicals directly attached to ring atoms
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/10: linked by a carbon chain containing aromatic rings
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.

## Claims

### Claim 1

A compound—
(a) having a formula II:
wherein
Y is C or N;
R1 is hydrogen or an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R1 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
n is 0, 1, or 2;
p is 0 or 1;
X is O or NH, or R1(CH2)n(X)p— is N-piperazinyl optionally N-substituted with alkyl;
m is 0 or 1;
R2 is hydrogen or halo, or R2 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R2 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R3 is hydrogen, alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, benzyl, hydroxyl, halo, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R4 is not present, or R4 is hydrogen, amino, alkyl, aryl, or benzyl; R4 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy;
R5 is alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, and halo;
R6 is not present, or R6 is hydrogen, amino, alkyl, aryl, or benzyl; R6 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy; and
R7 is hydrogen or halo, or R7 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R7 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
with the proviso that at least one of R4 and R6 is present;
(b) having a formula III:
wherein:
R1 is hydrogen or an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R1 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
n is 0, 1, or 2;
p is 0 or 1;
X is O or NH, or R1(CH2)n (X)p— is N-piperazinyl optionally N-substituted with alkyl;
m is 0 or 1;
R2 is hydrogen or halo, or R2 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R2 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R4 is hydrogen, amino, alkyl, aryl, or benzyl; R4 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy;
R5 is alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, and halo; and
R7 is hydrogen or halo, or R7 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R7 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
(c) having a formula IV:
wherein:
R1 is hydrogen or an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R1 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
n is 0, 1, or 2;
p is 0 or 1;
X is O or NH, or R1(CH2)n (X)p— is N-piperazinyl optionally N-substituted with alkyl;
Y is CH or N;
Z is C or N;
m is 0 or 1;
R2 is hydrogen or halo, or R2 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R2 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R4 is hydrogen, amino, alkyl, aryl, or benzyl; R4 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy;
R5 is alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, amino, hydroxyalkyl, —C(O)H, and halo; and
R7 is hydrogen or halo, or R7 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R7 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl; or
(d) having a formula V:
wherein:
R1 is hydrogen or an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R1 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
n is 0, 1, or 2;
p is 0 or 1;
X is O or NH, or R1(CH2)n (X)p— is N-piperazinyl optionally N-substituted with alkyl;
m is 0 or 1;
R2 is hydrogen or halo, or R2 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R2 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R5 is alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, benzyloxy, and halo; and
R7 is hydrogen or halo, or R7 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R7 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl
having a formula II:
wherein
Y is C or N;
R1 is hydrogen or an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R1 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
n is 0, 1, or 2;
p is 0 or 1;
X is O or NH, or R1(CH2)n (X)p— is N-piperazinyl optionally N-substituted with alkyl;
m is 0 or 1;
R2 is hydrogen or halo, or R2 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R2 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R3 is hydrogen, alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, benzyl, hydroxyl, halo, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R4 is not present, or R4 is hydrogen, amino, alkyl, aryl, or benzyl; R4 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy;
R5 is alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, and halo;
R6 is not present, or R6 is hydrogen, amino, alkyl, aryl, or benzyl; R6 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy; and
R7 is hydrogen or halo, or R7 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R7 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
with the proviso that at least one of R4 and R6 is present.

### Claim 2 (depends on 1)

The compound of claim 1 of formula II.

### Claim 3 (depends on 1)

The compound of claim 1, having a formula IIa:

### Claim 4 (depends on 1)

The compound of claim 1 of formula III.

### Claim 5 (depends on 4)

The compound of claim 4, having a formula IIIa or IIIb:

### Claim 6 (depends on 1)

The compound of claim 1 of formula IV.

### Claim 7 (depends on 1)

The compound of claim 1 of formula V.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a suitable pharmaceutical carrier, excipient, or diluent.

### Claim 9 (depends on 1)

A method of treating cancer comprising administering the compound of claim 1 or a pharmaceutical composition comprising the compound and a suitable pharmaceutical carrier, excipient, or diluent to a patient having cancer.

### Claim 10

A method for treating cancer comprising administering to a patient in need thereof a c-MYC targeting agent and an additional anti-cancer agent, wherein the c-MYC targeting agent decreases and/or inhibits c-MYC activity.

### Claim 11 (depends on 10)

The method of claim 10, wherein the additional anti-cancer agent is a chemotherapeutic agent or an immunotherapeutic agent.

### Claim 12 (depends on 11)

The method of claim 11, wherein the chemotherapeutic agent is an antimetabolite antineoplastic agent.

### Claim 13 (depends on 12)

The method of claim 12, wherein the antimetabolite antineoplastic agent is a nucleoside and/or nucleotide derivative.

### Claim 14 (depends on 13)

The method of claim 13, wherein the nucleoside and/or nucleotide derivative is cytosine arabinoside.

### Claim 15 (depends on 10)

The method of claim 10, wherein the immunotherapeutic agent is an anti-PD-1 antibody.

### Claim 16 (depends on 10)

The method of claim 10, wherein the cancer is a multiple myeloma, a leukemia, a non-small cell lung cancer, a colon cancer, a cancer of the central nervous system, a melanoma, an ovarian cancer, a renal cancer, a prostate cancer, or a breast cancer.

### Claim 17 (depends on 10)

The method of claim 10, wherein the c-MYC targeting agent is a compound:
(a) having a formula I:
wherein
R1 is hydrogen or R1 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, a benzoyl group, or a cycloheteroalkyl group, optionally R1 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, heteroaryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, —NH—C(O)—CH2—(OCH2)y—N3, NH—C(O)-alkylene-alkynyl optionally substituted with azido, —O-alkylene-alkynyl,
amino, nitro, and alkoxycarbonyl;
n is 0, 1, or 2;
p is 0 or 1;
X is O or NH, or R1(CH2)n (X)p— is N-piperazinyl optionally N-substituted with alkyl;
m is 0 or 1;
y is 3 or 4;
R2 is hydrogen or halo, or R2 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R2 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R3 is hydrogen, alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, benzyl, hydroxyl, halo, amido, hydrazonyl, carbonyl, carboxyl, cyano, and alkoxycarbonyl;
R4 is not present, or R4 is hydrogen, amino, alkyl, or R4 is aryl or benzyl; R4 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl (e.g., phenyl), hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy;
R5 is hydrogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, cyano, amino, amido, —C(O)H, hydroxyalkyl, or halo;
R6 is not present, or R6 is hydrogen, amino, alkyl, or R6 is aryl or benzyl; R6 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy, or R6 and R5 together form a ring structure having a formula
R7 is hydrogen or halo, or R7 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R7 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, sulfonyl-alkyl, and alkoxycarbonyl;
with the proviso that at least one of R4 and R6 is present;
with the proviso that if R5 is hydrogen, then p is 1 and m is 1; and
with the proviso that if R1(CH2)n (X)p— is hydrogen, hydroxyl, or alkyl, and R5 is hydroxyl, then m is 1, or at least one of R2 and R3 is not hydrogen;
(b) having a formula II:
wherein
Y is C or N;
R1 is hydrogen or an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R1 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
n is 0, 1, or 2;
p is 0 or 1;
X is O or NH, or R1(CH2)n (X)p— is N-piperazinyl optionally N-substituted with alkyl;
m is 0 or 1;
R2 is hydrogen or halo, or R2 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R2 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R3 is hydrogen, alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, benzyl, hydroxyl, halo, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R4 is not present, or R4 is hydrogen, amino, alkyl, aryl, or benzyl; R4 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy;
R5 is alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, and halo;
R6 is not present, or R6 is hydrogen, amino, alkyl, aryl, or benzyl; R6 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy; and
R7 is hydrogen or halo, or R7 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R7 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
with the proviso that at least one of R4 and R6 is present
(c) having a formula III:
wherein:
R1 is hydrogen or an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R1 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
n is 0, 1, or 2;
p is 0 or 1;
X is O or NH, or R1(CH2)n (X)p— is N-piperazinyl optionally N-substituted with alkyl;
m is 0 or 1;
R2 is hydrogen or halo, or R2 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R2 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R4 is hydrogen, amino, alkyl, aryl, or benzyl; R4 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy;
R5 is alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, and halo; and
R7 is hydrogen or halo, or R7 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R7 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
(d) having a formula IV:
wherein:
R1 is hydrogen or an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R1 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
n is 0, 1, or 2;
p is 0 or 1;
X is O or NH, or R1(CH2)n (X)p— is N-piperazinyl optionally N-substituted with alkyl;
Y is CH or N;
Z is C or N;
m is 0 or 1;
R2 is hydrogen or halo, or R2 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R2 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R4 is hydrogen, amino, alkyl, aryl, or benzyl; R4 optionally is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, alkoxycarbonyl, aryloxy, and alkylaryloxy;
R5 is alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, amino, hydroxyalkyl, —C(O)H, and halo; and
R7 is hydrogen or halo, or R7 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R7 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl; or
(e) having a formula V:
wherein:
R1 is hydrogen or an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R1 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, aryl, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
n is 0, 1, or 2;
p is 0 or 1;
X is O or NH, or R1(CH2)n (X)p— is N-piperazinyl optionally N-substituted with alkyl;
m is 0 or 1;
R2 is hydrogen or halo, or R2 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R2 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl;
R5 is alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, benzyloxy, and halo; and
R7 is hydrogen or halo, or R7 is an alkyl group, an aryl group, a benzyl group, a heteroaryl group, a cycloalkyl group, or a cycloheteroalkyl group, optionally R7 is substituted at one or more positions with one or more of alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, halo, cyano, amido, hydrazonyl, carbonyl, carboxyl, and alkoxycarbonyl.
